Real-world study of Pluvicto for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult male (18 years or older).
- You have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
- Your doctor has decided to start you on a treatment called lutetium (177Lu) vipivotide tetraxetan (also known as Pluvicto).
- You are not taking part in another clinical trial or research study at the same time.
- You are willing to answer questions about your quality of life for up to 1 year after starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for men with prostate cancer who are being treated with or are scheduled to receive the drug Pluvicto in South Korea. It aims to track real-world results and safety.
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
This study looks at how well Pluvicto, a targeted radiation therapy for advanced prostate cancer, works in real-world patients. It aims to learn more about survival outcomes for people like you.
This trial tests whether the drug Pluvicto (also known as lutetium Lu 177 vipivotide tetraxetan) can help African American men with a type of prostate cancer that has spread and no longer responds to hormone therapy. The treatment targets a protein called PSMA found on cancer cells, which may slow the cancer's growth.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.